Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2- breast cancer.

ABSTRACT:

SUBMITTER: Felip E 

PROVIDER: S-EPMC12331873 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature